JPMorgan Maintains Overweight Rating on United Therapeutics, Cuts Target to $695
JPMorgan cut its price target on United Therapeutics to $695 per share from $710 while maintaining its Overweight rating.
Related stories
South Korea’s Kospi falls 3%
M impact | EQUITY | Oct 30, 2026, 12:03 AM UTC
Coles Shares Slip as Competition Dents Early Second-Quarter Sales
Coles shares slipped as intense competition weighed on early second-quarter sales.
L impact | EQUITY | Oct 30, 2026, 12:03 AM UTC
Toggle Holdings shares indicated for sale
L impact | EQUITY | Oct 30, 2026, 12:02 AM UTC
South Korea’s Kospi Opens 3.0% Lower at 5760.35
M impact | EQUITY | Oct 30, 2026, 12:01 AM UTC
Nikkei Opens 0.5% Lower at 64,344.37
The Nikkei Stock Average opened 0.5% lower, dragged by electronics and metals stocks.
M impact | EQUITY | Oct 30, 2026, 12:01 AM UTC
SK Hynix shares fall 5%
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC